We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Urinary Analysis in Early Pregnancy Predicts Likelihood of Preterm Birth

By LabMedica International staff writers
Posted on 24 Jul 2014
Analysis of metabolites in the urine during the early stages of pregnancy was found to be an effective approach for predicting the likelihood of a preterm birth.

Preterm birth (PB) and fetal growth restriction (FGR) convey high risk of infant mortality and morbidity, as well as increasing the chance of developing chronic disease in later life. More...
Biomarkers identified early in pregnancy could predict poor birth outcomes and aid in their prevention and management.

Investigators at Imperial College London (United Kingdom) and the University of Crete (Greece) used proton nuclear magnetic resonance spectroscopy to analyze metabolites in urine samples obtained at the first ultrasound appointment from 438 pregnant women in the Rhea cohort. The Rhea cohort is a large population case-control mother-child study that started in Crete in 2007.

Results revealed that elevated urinary levels of lysine were associated with spontaneous premature birth. Decreased levels of acetate, formate, tyrosine, and trimethylamine were associated with poor fetal development. Women with decreased levels of these urine metabolites also showed signs of an increased risk of diabetes, such as higher blood insulin. Increased levels of an N-acetylated glycoprotein were significantly associated with induced preterm birth (IPB) in overweight and obese women only.

Senior author Dr. Hector Keun, senior lecturer in biological chemistry at Imperial College London, said, "While we know that metabolism in the mother changes substantially during pregnancy to help supply the growing fetus with nutrients, we were surprised to see so early in pregnancy a link between metabolites that we could easily detect in a urine sample and low birth weight. Our findings imply that it could be possible to improve the identification of women at higher risk of delivering smaller babies or premature delivery using noninvasive metabolic profiling technology early in pregnancy. Future investigation of the factors that produce the molecules associated with these pregnancy outcomes should improve our understanding of the genetic and environmental factors that influence restricted fetal growth and thus help us to reduce the likelihood of these events. We will also go on to test if exposure to these metabolites during pregnancy has a lasting impact on child development after birth."

The urine metabolites study was published in the July 11, 2014, online edition of the journal BMC Medicine.


Related Links:

Imperial College London

University of Crete




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.